Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 6/2008 | EBR Systems | Series C | 35M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2007 | AnaptysBio | Series B | 0 |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 10/2003 | Cotherix | Series C | 55M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 6/2003 | Xoft | Series B | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 5/2005 | Xoft | Series C | 0 |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 4/2008 | Stromedix | Series B | 25M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 3/2006 | PowerVision | Series A | 2M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 9/2021 | HilleVax | Equity | 135M |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 12/2003 | FlowCardia | Series B | 12M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 9/2002 | Glaukos | Series A | 10M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 3/2009 | Stemgent | Series B | 14M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2022 | Metagenomi | Series B | 0 |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 3/2021 | Amunix | Series B | 117M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 1/1996 | Corixa | Venture Round | - |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 8/2007 | FlowCardia | Series C | 0 |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 1/2005 | PowerVision | Series A | 4.4M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 4/2012 | Alcresta | Series A | 10M |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 3/2007 | Stromedix | Series A | 1M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 5/2016 | Aptinyx | Series A | 0 |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 2/2011 | Chimerix | Series F | 45M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1996 | ViroPharma | Funding Round | - |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | CVRx | Series D | 65M |
| 7/2011 | PowerVision | Series C | 24M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 12/2007 | Barosense | Series C | 11.2M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 11/2017 | Mavupharma | Series A | 0 |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 4/2001 | Fast Track | Series C | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2020 | Inipharm | Series A | 0 |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 3/2019 | Scout Bio | Series B | 20M |
| 4/2010 | Achaogen | Series C | 56M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
